Literature DB >> 19007534

Virus-induced vasculitis.

Hisham Sharlala1, Ade Adebajo.   

Abstract

There is a growing understanding of the different syndromes that have a definite, and in some cases a possible, association with viral infections. Hepatitis C virus-associated mixed cryoglobulinemias and hepatitis B virus-associated polyarteritis nodosa are examples of a vasculitis with a definite viral association. However, various types of cutaneous vasculitis are examples of a vasculitis with only a possible association with a viral infection.

Entities:  

Mesh:

Year:  2008        PMID: 19007534      PMCID: PMC7088730          DOI: 10.1007/s11926-008-0073-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  17 in total

1.  Cloning the arterial IgA antibody response during acute Kawasaki disease.

Authors:  Anne H Rowley; Stanford T Shulman; Francesca L Garcia; Judith A Guzman-Cottrill; Masaru Miura; Hannah L Lee; Susan C Baker
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

2.  Cutaneous necrotizing vasculitis associated with hepatitis C virus infection.

Authors:  Amer A Alkhatib; Douglas G Adler
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

Review 3.  New developments in the search for the etiologic agent of Kawasaki disease.

Authors:  Anne H Rowley; Stanford T Shulman
Journal:  Curr Opin Pediatr       Date:  2007-02       Impact factor: 2.856

4.  Virological analysis and phenotypic characterization of peripheral blood lymphocytes of hepatitis C virus-infected patients with and without mixed cryoglobulinaemia.

Authors:  D Sansonno; G Lauletta; M Montrone; F A Tucci; L Nisi; F Dammacco
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

Review 5.  Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations.

Authors:  Domenico Sansonno; Franco Dammacco
Journal:  Lancet Infect Dis       Date:  2005-04       Impact factor: 25.071

6.  Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients.

Authors:  Loïc Guillevin; Alfred Mahr; Patrice Callard; Pascal Godmer; Christian Pagnoux; Emmanuelle Leray; Pascal Cohen
Journal:  Medicine (Baltimore)       Date:  2005-09       Impact factor: 1.889

7.  Hepatitis B-associated vasculitis in Alaska Natives: viral genotype, clinical and serologic outcome.

Authors:  Kathy J Hurlburt; Brian J McMahon; Josephine P Simonetti; Stephen E Livingston; Lisa R Bulkow; Mary M Snowball; Vladimir P Chulanov; Omana P Nainan; James L Williams
Journal:  Liver Int       Date:  2007-06       Impact factor: 5.828

8.  Cryoglobulinaemia vasculitis in patients coinfected with HIV and hepatitis C virus.

Authors:  David Saadoun; Laurent Aaron; Mathieu Resche-Rigon; Gilles Pialoux; Jean-Charles Piette; Patrice Cacoub
Journal:  AIDS       Date:  2006-04-04       Impact factor: 4.177

9.  Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response.

Authors:  Dan-Avi Landau; David Saadoun; Philippe Halfon; Michelle Martinot-Peignoux; Patrick Marcellin; Elena Fois; Patrice Cacoub
Journal:  Arthritis Rheum       Date:  2008-02

10.  Epstein-Barr virus antibodies in Kawasaki disease.

Authors:  Soon-Ju Lee; Kyung-Yil Lee; Ji-Whan Han; Joon-Sung Lee; Kyung-Tai Whang
Journal:  Yonsei Med J       Date:  2006-08-31       Impact factor: 2.759

View more
  2 in total

Review 1.  Skin manifestations as potential symptoms of diffuse vascular injury in critical COVID-19 patients.

Authors:  Afsaneh Sadeghzadeh-Bazargan; Mahdi Rezai; Niloufar Najar Nobari; Samaneh Mozafarpoor; Azadeh Goodarzi
Journal:  J Cutan Pathol       Date:  2021-06-15       Impact factor: 1.458

Review 2.  SARS-CoV-2, COVID-19, skin and immunology - What do we know so far?

Authors:  Natalijia Novak; Wenming Peng; Mirjam C Naegeli; Christina Galvan; Isabel Kolm-Djamei; Charlotte Brüggen; Beatriz Cabanillas; Peter Schmid-Grendelmeier; Alba Catala
Journal:  Allergy       Date:  2020-08-12       Impact factor: 14.710

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.